These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29593491)

  • 1. Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?
    Post MR; Lieberman OJ; Mosharov EV
    Front Neurosci; 2018; 12():161. PubMed ID: 29593491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The raphe nuclei are the early lesion site of gastric
    Zhang C; Bo R; Zhou T; Chen N; Yuan Y
    Acta Pharm Sin B; 2024 May; 14(5):2057-2076. PubMed ID: 38799632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
    Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
    J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ion channel dysregulation and cellular adaptations to alpha-synuclein in stressful pacemakers of the parkinsonian brainstem.
    Chiu WH; Wattad N; Goldberg JA
    Pharmacol Ther; 2024 Aug; 260():108683. PubMed ID: 38950869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson's disease.
    Matschke LA; Komadowski MA; Stöhr A; Lee B; Henrich MT; Griesbach M; Rinné S; Geibl FF; Chiu WH; Koprich JB; Brotchie JM; Kiper AK; Dolga AM; Oertel WH; Decher N
    Sci Rep; 2022 Feb; 12(1):3180. PubMed ID: 35210472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
    Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
    Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
    Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
    J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
    Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
    J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic energy decline coupled dysregulation of catecholamine metabolism in physiologically highly active neurons: implications for selective neuronal death in Parkinson's disease.
    Wimalasena K; Adetuyi O; Eldani M
    Front Aging Neurosci; 2024; 16():1339295. PubMed ID: 38450382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral overexpression of human alpha-synuclein in mouse substantia nigra dopamine neurons results in hyperdopaminergia but no neurodegeneration.
    Moreno SIG; Limani F; Ludwig I; Gilbert C; Pifl C; Hnasko TS; Steinkellner T
    bioRxiv; 2024 May; ():. PubMed ID: 38746104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutathione
    Jewett M; Dickson E; Brolin K; Negrini M; Jimenez-Ferrer I; Swanberg M
    Front Neurol; 2018; 9():222. PubMed ID: 29681884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.
    Proença MB; Dombrowski PA; Da Cunha C; Fischer L; Ferraz AC; Lima MM
    Neuropharmacology; 2014 Jan; 76 Pt A():118-26. PubMed ID: 24012539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
    Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
    Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of dopaminergic neuron loss in Parkinson's disease.
    Surmeier DJ
    FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease.
    Mor DE; Ischiropoulos H
    J Exp Neurosci; 2018; 12():1179069518761360. PubMed ID: 29559809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.